Varma Mutual Pension Insurance Co Takes Position in AbbVie Inc. $ABBV

Key Points

• Varma Mutual Pension Insurance Co. initiated a sizable AbbVie position, buying 270,367 shares worth approximately $68.0 million in the second quarter. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie exceeded quarterly expectations with adjusted EPS of $3.65 versus the $3.61 consensus and revenue of $16.99 billion, up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $275.95 versus the reported share price of $259.87. AbbVie also pays a quarterly dividend of $1.73, equivalent to a 2.7% annualized yield.

Varma Mutual Pension Insurance Co bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 270,367 shares of the company's stock, valued at approximately $68,035,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. ACT Advisors LLC. lifted its holdings in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC grew its stake in shares of AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after purchasing an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC increased its holdings in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after purchasing an additional 43 shares in the last quarter. Fielder Capital Group LLC increased its holdings in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock valued at $637,000 after purchasing an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC lifted its stake in shares of AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock valued at $751,000 after purchasing an additional 44 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $259.87 on Wednesday. The firm has a fifty day moving average of $253.69 and a 200 day moving average of $229.43. The firm has a market cap of $459.14 billion, a PE ratio of 73.41, a PEG ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm posted $2.97 earnings per share. The company's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and introduced HA 5 Hydra Collagen Facial Mist. Clinical testing reportedly showed a 30% reduction in skin dryness after two weeks, supporting AbbVie’s aesthetics and consumer-health growth strategy. SkinMedica Adds Barrier Calming Cream
• Positive Sentiment: AbbVie is cited as a potential beneficiary of an aging population, with its immunology portfolio positioned to capture long-term healthcare demand. Aging Population Drives Healthcare Growth
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. The event could provide updates on its pipeline, Humira replacement products and financial outlook, but no new information was announced yet. AbbVie Wells Fargo Healthcare Conference
• Neutral Sentiment: Investors are largely waiting for AbbVie’s next earnings update, leaving the stock without a major new near-term catalyst. AbbVie Stock Holds Steady
• Neutral Sentiment: New 340B-related court developments could affect drug-company pricing and reimbursement, but the article does not identify a specific immediate impact on AbbVie. 340B Court Updates
• Negative Sentiment: Erste Group Bank reduced its fiscal 2026 EPS estimate for AbbVie, signaling somewhat more cautious expectations for earnings growth. AbbVie FY2026 EPS Estimates Reduced

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. BMO Capital Markets increased their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Piper Sandler upped their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. HSBC restated a "buy" rating and set a $300.00 target price on shares of AbbVie in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $275.95.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source